MiNK Therapeutics Q3 2024 net loss narrows to $1.8M; cash at $6.3M

MiNK Therapeutics, Inc.

2024-Q3 EPS reported -$0.22

Net loss of $1.8M ($0.05 per share) improved from $5.1M ($0.15) in Q3 2023.
Cash and equivalents $6.3M; operations used $3.0M in Q3, down from $4.2M YoY.
R&D expenses fell to $541K from $3.4M; total operating loss $1.9M vs $5.2M.
Phase 2 gastric cancer trial data expected at a major conference in early 2025.
Dr. Robert Kadlec joined board; new collaboration with Autonomous Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.